4-(2-Chloro-5-nitropyrimidin-4-yl)oxy-3,5-dimethylbenzonitrile | 332435-47-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-Chloro-5-nitropyrimidin-4-yl)oxy-3,5-dimethylbenzonitrile
• CAS: 332435-47-9
• 化学式: C₁₃H₉ClN₄O₃
• 分子量: 304.692
• InChiKey: PZLGJDXKOSRAPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-Chloro-5-nitropyrimidin-4-yl)oxy-3,5-dimethylbenzonitrile 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 丙酮 为溶剂， 反应 193.84h， 生成 N-[2-(4-cyanoanilino)-4-(4-cyano-2,6-dimethylphenoxy)pyrimidin-5-yl]acetamide
  参考文献：
  名称：

  PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES

  摘要：

  公开号：

  EP1282607B1
• 作为产物：
  描述：

  3,5-二甲基-4-羟基苯甲腈 、 2,4-二氯-5 硝基嘧啶 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(2-Chloro-5-nitropyrimidin-4-yl)oxy-3,5-dimethylbenzonitrile
  参考文献：
  名称：

  Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses

  摘要：

  Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.068

文献信息

• HIV REPLICATION INHIBITING PYRIMIDINES
  申请人：De Corte Bart

  公开号：US20080176880A1

  公开（公告）日：2008-07-24

  This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a 1 =a 2 -a 3 =a 4 - forms a phenyl, pyridinyl; pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5. R 1 is hydrogen, al, formyl, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 alkyloxy-carbonyl, substituted C 1-6 alkyl, or substituted C 1-6 alkyloxyC 1-6 alkylcarbonyl; each R 2 independently is hydroxy, halo, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═CO)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-7 cycloalkyl; or L is —X—R 3 wherein R 3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR 1 —, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O) 2 —; Q is hydrogen, C 1-6 alkyl, halo, polyhalo-C 1-6 alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —C(—O)R 6 , —C(═NH)R 6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

  本发明涉及使用式中化合物的使用，其中N-氧化物，药学上可接受的加成盐，季铵盐及其立体化学异构体形式，其中-a1=a2-a3=a4-形成苯基，吡啶基；嘧啶基，吡嗪基或吡咯基与附加的乙烯基；n为0至4；如有可能为5。R1为氢，醇基，甲酰基，C1-6烷基羰基，C1-6烷基，C1-6烷氧基羰基，取代的C1-6烷基或取代的C1-6烷氧基C1-6烷基羰基；每个R2独立地为羟基，卤素，可选取代的C1-6烷基，C2-6烯基或C2-6炔基，C3-7环烷基，C1-6烷氧基，C1-6烷氧基羰基，羧基，氰基，硝基，氨基，单烷基或双(C1-6烷基)氨基，多卤代甲基，多卤代甲氧基，多卤代甲硫基，-S(═O)pR6，-NH-S(═O)pR6，-C(═O)R6，-NHC(═CO)H，-C(═O)NHNH2，-NHC(═O)R6，-C(═NH)R6或5-成员杂环环；p为1或2；L为可选取代的C1-10烷基，C2-10烯基，C2-10炔基或C3-7环烷基；或L为-X-R3，其中R3为可选取代的苯基，吡啶基，嘧啶基，吡咯基或吡嗪基；X为-NR1-，-NH-NH-，-N═N-，-O-，-C(═O)-，-CHOH-，-S-，-S(═O)-或-S(═O)2-；Q为氢，C1-6烷基，卤素，多卤代C1-6烷基或可选取代的氨基基团；Y代表羟基，卤素，C3-7环烷基，可选取代的C1-6烷基，C2-6烯基或C2-6炔基，C1-6烷氧基，C1-6烷氧基羰基，羧基，氰基，硝基，氨基，单烷基或双(C1-6烷基)氨基，多卤代甲基，多卤代甲氧基，多卤代甲硫基，-S(═O)pR6，-NH-S(═O)pR6，-C(═O)R6，-NHC(═O)H，-C(═O)NHNH2，-C(—O)R6，-C(═NH)R6或芳基；芳基为可选取代的苯基；Het为可选取代的杂环基团；用于制造治疗感染艾滋病毒（HIV）的患者的药物。
• ANTIVIRAL COMPOSITIONS
  申请人：Verreck Geert

  公开号：US20070196478A1

  公开（公告）日：2007-08-23

  The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.

  本发明涉及抗病毒化合物的制药组合物，可用于治疗哺乳动物，特别是人类患有病毒感染的情况。这些组合物包括通过熔融挤出包含一种或多种抗病毒化合物和一种或多种适当的水溶性聚合物的混合物所获得的颗粒，并随后对该熔融挤出混合物进行研磨。
• US7241458B1
  申请人：——

  公开号：US7241458B1

  公开（公告）日：2007-07-10
• US7763631B2
  申请人：——

  公开号：US7763631B2

  公开（公告）日：2010-07-27
• US7887845B2
  申请人：——

  公开号：US7887845B2

  公开（公告）日：2011-02-15